Literature DB >> 18758795

Expression of matrix metalloproteinases and their inhibitors in cords and nodules of patients with Dupuytren's disease.

Dietmar Ulrich1, Franziska Ulrich, Andrzej Piatkowski, Norbert Pallua.   

Abstract

INTRODUCTION: Dupuytren's disease is a fibroproliferative disorder characterized by thickening of the palmar fascia. Several studies indicate that MMPs and TIMPs may play a key role in the onset or progression of Dupuytren's disease and related disorders. In this study, we used a quantitative reverse-transcription PCR methodology to profile the expression of TIMP1, TIMP2, MMP2, and MMP9 in nodule and cord tissue from patients with Dupuytren's disease and compared this with normal palmar fascia taken at carpal tunnel release.
MATERIALS AND METHODS: Tissue from patients with Dupuytren's disease was taken at fasciectomy (n = 30; 23 men and 7 women; average age 61.3 +/- 9.5 years). Samples were divided into regions of nodule and cord according to gross morphology. Normal fascia was taken from patients without Dupuytren's contracture who had carpal tunnel release (n = 30; 14 men and 16 women; average age 63 +/- 11 years). Expression of mRNA was calculated using a relative quantification method (Pfaffl). Statistical analysis was performed using the Mann-Whitney test. The level of significance was considered to be P < 0.05.
RESULTS: In comparison to normal fascia, the cords and nodules from patients with Dupuytren's disease showed significant upregulation for TIMP1 and TIMP2 (P < 0.05). The expression of TIMP1 was significantly higher in nodules in comparison to cord tissue (P < 0.05). The expression of MMP2 was significantly upregulated in tissue of patients with Dupuytren's contracture in comparison to normal tissue (P < 0.05). The expression of MMP2 was significantly higher in nodules in comparison to cord tissue (P < 0.05). There was no significant difference in the relative expression of MMP9 in nodules and cord tissue of patients with Dupuytren's contracture in comparison to normal fascia from patients with carpal tunnel syndrome.
CONCLUSIONS: The balance between MMPs and their natural inhibitors is disturbed in patients with Dupuytren's disease. The decrease in MMP-to-TIMP expression can cause increased synthesis and deposition of collagen, leading to palmar fibromatosis. The high expression of MMP2 may represent an unsuccessful attempt to reduce collagen deposition. In the future, a treatment that downregulates TIMPs but increases the activity of MMPs may be an appropriate therapy for Dupuytren's disease.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18758795     DOI: 10.1007/s00402-008-0726-3

Source DB:  PubMed          Journal:  Arch Orthop Trauma Surg        ISSN: 0936-8051            Impact factor:   3.067


  11 in total

1.  Update on the role of molecular factors and fibroblasts in the pathogenesis of Dupuytren's disease.

Authors:  Massimiliano Tripoli; Adriana Cordova; Francesco Moschella
Journal:  J Cell Commun Signal       Date:  2016-06-07       Impact factor: 5.782

Review 2.  Scientific understanding and clinical management of Dupuytren disease.

Authors:  Barbara Shih; Ardeshir Bayat
Journal:  Nat Rev Rheumatol       Date:  2010-11-09       Impact factor: 20.543

3.  The Role of Functional Polymorphisms in the Extracellular Matrix Modulation-Related Genes on Dupuytren's Contracture.

Authors:  Gediminas Samulenas; Ruta Insodaite; Edita Kunceviciene; Roberta Poceviciute; Lorena Masionyte; Urte Zitkeviciute; Loreta Pilipaityte; Alina Smalinskiene
Journal:  Genes (Basel)       Date:  2022-04-23       Impact factor: 4.141

4.  Dupuytren's Disease: Review of the Current Literature.

Authors:  Morsi Khashan; Peter J Smitham; Wasim S Khan; Nicholas J Goddard
Journal:  Open Orthop J       Date:  2011-07-28

Review 5.  Dupuytren's: a systems biology disease.

Authors:  Samrina Rehman; Royston Goodacre; Philip J Day; Ardeshir Bayat; Hans V Westerhoff
Journal:  Arthritis Res Ther       Date:  2011-09-12       Impact factor: 5.156

6.  Inflammatory Gene Expression Upon TGF-β1-Induced p38 Activation in Primary Dupuytren's Disease Fibroblasts.

Authors:  Maro Bujak; Ivana Ratkaj; Elitza Markova-Car; Davor Jurišić; Anita Horvatić; Srđan Vučinić; Jonatan Lerga; Mirela Baus-Lončar; Krešimir Pavelić; Sandra Kraljević Pavelić
Journal:  Front Mol Biosci       Date:  2015-12-08

7.  The congenital clubfoot - immunohistological analysis of the extracellular matrix.

Authors:  Arno Kerling; Gisela Stoltenburg-Didinger; Lena Grams; Uwe Tegtbur; Hauke Horstmann; Momme Kück; Holger Mellerowicz
Journal:  Orthop Res Rev       Date:  2018-08-23

Review 8.  Recent advances in the understanding of Dupuytren's disease.

Authors:  Thomas Layton; Jagdeep Nanchahal
Journal:  F1000Res       Date:  2019-02-28

9.  THE POLYMORPHISM OF METALLOPROTEINASES 1 AND 13 AND POSTTRAUMATIC ELBOW STIFFNESS.

Authors:  Gustavo DE Mello Ribeiro Pinto; Jorge Henrique Assunção; Maria Cristina Leme Godoy Dos Santos; Alexandre Leme Godoy-Santos; Mauro Emilio Conforto Gracitelli; Eduardo Angeli Malavolta; Fernando Brandão DE Andrade E Silva; Arnaldo Amado Ferreira Neto
Journal:  Acta Ortop Bras       Date:  2022-01-28       Impact factor: 0.513

10.  Matrix and cell phenotype differences in Dupuytren's disease.

Authors:  Marike M van Beuge; Evert-Jan P M Ten Dam; Paul M N Werker; Ruud A Bank
Journal:  Fibrogenesis Tissue Repair       Date:  2016-06-29
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.